YIH
PRLD icon

Y-Intercept (HK)’s Prelude Therapeutics PRLD Stock Holding History

Y-Intercept (HK)’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-47,788
Closed -$38.7K – 1938
2025
Q2 		$38.7K Buy
+47,788
New +$41.4K ﹤0.01% 1569
2024
Q3 		– Sell
-18,839
Closed -$71.8K – 1706
2024
Q2 		$71.8K Buy
+18,839
New +$76.7K ﹤0.01% 1283

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Y-Intercept (HK)'s PRLD Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Prelude Therapeutics (PRLD) in Q3 2025, closing a stake of 47,788 shares — an estimated $38.7K sold.

Y-Intercept (HK) first reported a position in PRLD in Q2 2024 and held it in 2 quarters. The position peaked at $71.8K in Q2 2024. 47 funds tracked by Wall St. Rank hold PRLD as of Q3 2025.

  • Y-Intercept (HK) reported no remaining Prelude Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 47,788 Prelude Therapeutics shares in Q3 2025, an estimated $38.7K.
  • Y-Intercept (HK) first reported a position in Prelude Therapeutics in Q2 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s Prelude Therapeutics position peaked at $71.8K in Q2 2024.
  • 47 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.